Relationship Between Effect Duration of Rocuronium and Body Composition Analysis Data.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center, Sungkyunkwan University, School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients with ASA class I-II undergoing total intravenous general anesthesia
Exclusion Criteria:
- too overweight (over 111.11kg, which corresponds to less than 0.45mg/kg of induction dose of rocuronium)
- too underweight (under 41.67kg, which corresponds to more than 1.2mg/kg of induction dose of rocuronium)
- pregnancy
- prediagnosed muscle or nerve related disease
- unsuitable for body composition analysis using bioelectrical impedance method
- unsuitable for neuromuscular block monitoring
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
rocuronium
The patient will be given 50mg of rocuronium intravenously for induction.
|
Patients will undergo body composition analysis using bioelectical impedance method before anesthesia.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
time to TOF1
Time Frame: up to 1 hour after rocuronium administration during induction of anesthesia
|
correlation between the time from induction to recovery of 1st TOF twitch and age, sex, ASA class, body weight, and body composition analysis data
|
up to 1 hour after rocuronium administration during induction of anesthesia
|
|
time to TOF4
Time Frame: up to 1.5 hour after rocuronium administration during induction of anesthesia
|
correlation between the time from induction to recovery of 4th TOF twitch and age, sex, ASA class, body weight, and body composition analysis data
|
up to 1.5 hour after rocuronium administration during induction of anesthesia
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
time to loss of TOF
Time Frame: up to 5 minutes after rocuronium administration during induction of anesthesia
|
correlation between the time from injection of rocuronium to complete loss of TOF twitch and age, sex, ASA class, body weight, and body composition analysis data
|
up to 5 minutes after rocuronium administration during induction of anesthesia
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SMC 2022-07-160
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.